

Mark Clemons

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11682631/mark-clemons-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26

papers

3,660

citations

17

h-index

27

g-index

27

ext. papers

4,101

ext. citations

10

avg, IF

4.78

L-index

#	Paper	IF	Citations
26	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. <i>Lancet Oncology, The</i> , 2011 , 12, 852-61	21.7	883
25	Estrogen and the risk of breast cancer. <i>New England Journal of Medicine</i> , 2001 , 344, 276-85	59.2	789
24	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 904-916	21.7	330
23	PK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. <i>Cell Metabolism</i> , 2015 , 22, 577-89	24.6	308
22	Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. <i>Clinical Breast Cancer</i> , 2009 , 9, 29-33	3	303
21	Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4175-83	2.2	292
20	A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. <i>Supportive Care in Cancer</i> , 2008 , 16, 577-83	3.9	151
19	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2013 , 15, R88	8.3	139
18	Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. <i>Cancer Treatment Reviews</i> , 2012 , 38, 708-14	14.4	128
17	Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. <i>Molecular and Cellular Biology</i> , 2012 , 32, 2979-91	4.8	72
16	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. <i>European Journal of Cancer</i> , 2018 , 103, 147-154	7.5	38
15	Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies. <i>Lancet Oncology, The</i> , 2002 , 3, 611-9	21.7	32
14	Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?. <i>Lancet Oncology, The</i> , 2009 , 10, 933-5	21.7	31
13	Identifying menopause in breast cancer patients: considerations and implications. <i>Breast Cancer Research and Treatment</i> , 2007 , 104, 115-20	4.4	27
12	Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. <i>Oncologist</i> , 2006 , 11, 227-33	5.7	27
11	Platinum-based chemotherapy in triple-negative advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 146, 567-72	4.4	26
10	Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007 , 30, 297-302	2.7	19

9	Can bone markers guide more effective treatment of bone metastases from breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2006 , 97, 81-90	4.4	15
8	Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT). <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 93-101	4.4	10
7	Perspectives on the future of bisphosphonate use in breast cancer patients. <i>Seminars in Oncology</i> , 2004 , 31, 87-91	5.5	9
6	Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients. <i>Supportive Care in Cancer</i> , 2017 , 25, 1881-1886	3.9	8
5	Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. <i>Oncology Letters</i> , 2014 , 7, 866-870	2.6	7
4	Management of the menopause in cancer survivors. <i>Cancer Treatment Reviews</i> , 2002 , 28, 321-33	14.4	7
3	Should oral bisphosphonates be standard of care in women with early breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2005 , 90, 315-8	4.4	5
2	Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial). <i>PLoS ONE</i> , 2018 , 13, e0199297	3.7	2
1	Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 343-350	4.4	2